NASDAQ:ORIC • US68622P1093
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ORIC PHARMACEUTICALS INC (ORIC).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-24 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-02-24 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-01-07 | Piper Sandler | Initiate | Overweight |
| 2025-12-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-12-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-20 | Evercore ISI Group | Initiate | Outperform |
| 2025-11-18 | Wolfe Research | Initiate | Peer Perform |
| 2025-11-18 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-11-14 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-14 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-13 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-07-08 | Ladenburg Thalmann | Initiate | Buy |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 720.11% | N/A 265.76% | N/A 130.32% | N/A 49.62% | N/A 28.11% | |||||||||
| EBITDA YoY % growth | -21.47M | -27.54M -28.27% | -48.38M -75.67% | -77.97M -61.16% | -90.8M -16.46% | -109.748M -20.87% | -141.788M -29.19% | -141.784M 0.00% | N/A -10.98% | N/A -12.34% | N/A -0.62% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.37M | -28.57M -27.72% | -49.35M -72.73% | -78.87M -59.82% | -91.77M -16.36% | -110.78M -20.71% | -142.895M -28.99% | -143.004M -0.08% | N/A -13.15% | N/A -16.41% | N/A -14.73% | N/A -14.52% | N/A 73.42% | N/A 606.64% | N/A 84.20% | N/A 47.75% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -6.22 | -2.07 66.72% | -2.25 -8.70% | -1.96 12.89% | -1.82 7.14% | -1.52 16.48% | N/A 5.42% | N/A -10.09% | N/A -9.45% | N/A -1.43% | N/A 78.52% | N/A 772.97% | N/A 79.92% | N/A 46.43% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.33 21.13% | -0.35 24.94% | -0.37 -12.37% | -0.38 -27.80% | -0.39 -17.94% | -0.40 -13.62% | -0.41 -10.30% | -0.40 -5.09% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | -35.593M -9.80% | -38.42M 0.08% | -40.328M -12.74% | -42.763M -28.30% | -36.72M -3.17% | -42.84M -11.50% | -44.88M -11.29% | -45.9M -7.34% |
| EBIT Q2Q % growth | -37.306M -14.02% | -39.573M -1.30% | -41.824M -14.05% | -43.733M -26.58% | -42.228M -13.19% | -45.39M -14.70% | -46.648M -11.53% | -47.09M -7.68% |
All data in USD
21 analysts have analysed ORIC and the average price target is 21.42 USD. This implies a price increase of 110.21% is expected in the next year compared to the current price of 10.19.
ORIC PHARMACEUTICALS INC (ORIC) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of ORIC PHARMACEUTICALS INC (ORIC) is -0.33 USD and the consensus revenue estimate is 0 USD.